RU2020100891A3 - - Google Patents

Download PDF

Info

Publication number
RU2020100891A3
RU2020100891A3 RU2020100891A RU2020100891A RU2020100891A3 RU 2020100891 A3 RU2020100891 A3 RU 2020100891A3 RU 2020100891 A RU2020100891 A RU 2020100891A RU 2020100891 A RU2020100891 A RU 2020100891A RU 2020100891 A3 RU2020100891 A3 RU 2020100891A3
Authority
RU
Russia
Application number
RU2020100891A
Other languages
Russian (ru)
Other versions
RU2816994C2 (ru
RU2020100891A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020100891A3 publication Critical patent/RU2020100891A3/ru
Publication of RU2020100891A publication Critical patent/RU2020100891A/ru
Application granted granted Critical
Publication of RU2816994C2 publication Critical patent/RU2816994C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2020100891A 2017-06-20 2018-06-20 Антитела к bcma, содержащие только тяжелую цепь RU2816994C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522355P 2017-06-20 2017-06-20
US62/522,355 2017-06-20
PCT/US2018/038549 WO2018237037A2 (en) 2017-06-20 2018-06-20 Anti-bcma heavy chain-only antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2024106562A Division RU2024106562A (ru) 2017-06-20 2018-06-20 Антитела к bcma, содержащие только тяжелую цепь

Publications (3)

Publication Number Publication Date
RU2020100891A3 true RU2020100891A3 (enExample) 2021-07-20
RU2020100891A RU2020100891A (ru) 2021-07-20
RU2816994C2 RU2816994C2 (ru) 2024-04-09

Family

ID=

Also Published As

Publication number Publication date
AU2018289515A1 (en) 2020-02-06
SG11201912774RA (en) 2020-01-30
CN117866097A (zh) 2024-04-12
KR102742528B1 (ko) 2024-12-16
JP7303126B2 (ja) 2023-07-04
JP2024127941A (ja) 2024-09-20
KR20250007003A (ko) 2025-01-13
IL271194A (en) 2020-01-30
IL271194B1 (en) 2024-06-01
IL271194B2 (en) 2024-10-01
WO2018237037A2 (en) 2018-12-27
KR20200018498A (ko) 2020-02-19
IL312322A (en) 2024-06-01
CA3067584A1 (en) 2018-12-27
AU2018289515B2 (en) 2025-04-24
ZA201908214B (en) 2024-04-24
CN110891971B (zh) 2024-01-12
AU2018289515A2 (en) 2020-02-20
MX2024001394A (es) 2024-02-27
WO2018237037A3 (en) 2019-02-07
CN110891971A (zh) 2020-03-17
ZA202311311B (en) 2025-04-30
RU2020100891A (ru) 2021-07-20
EP3642237A2 (en) 2020-04-29
US20210147564A1 (en) 2021-05-20
BR112019026907A2 (pt) 2020-06-30
US20240124599A1 (en) 2024-04-18
US11970540B2 (en) 2024-04-30
JP2022174169A (ja) 2022-11-22
JP2020524506A (ja) 2020-08-20

Similar Documents

Publication Publication Date Title
BR122021024397A2 (enExample)
BR122021000189A2 (enExample)
BR112020006084A8 (enExample)
BR122022025811B8 (enExample)
BR122021023687A2 (enExample)
BR122021014832A2 (enExample)
BR122022003522A2 (enExample)
BR112020008820A2 (enExample)
BR202017025154U2 (enExample)
BR202017021228U2 (enExample)
BR202017020981U2 (enExample)
BR202017017068U2 (enExample)
BR202017016984U2 (enExample)
BR202017016924U2 (enExample)
BR202017012548U2 (enExample)
BR202017011220U2 (enExample)
BR202017010814U2 (enExample)
BR202017010373U2 (enExample)
BR202017009870U2 (enExample)
BR202017006953U2 (enExample)
BR202017004898U2 (enExample)
BR202017002937U2 (enExample)
BR202017002826U2 (enExample)
CN303997836S (enExample)
CN303996223S (enExample)